ProQR Therapeutics BV (PRQR) — Cash Flow-to-Debt Ratio
ProQR Therapeutics BV (PRQR) has a Cash Flow-to-Debt Ratio of -0.18x as of September 2025, meaning its operating cash flow of $-12.23 Million could theoretically repay 0% of its total liabilities ($67.28 Million) in one year. Explore PRQR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ProQR Therapeutics BV Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for ProQR Therapeutics BV across 12 annual periods. Also explore ProQR Therapeutics BV asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for ProQR Therapeutics BV (2013–2024)
Year-by-year debt coverage analysis for ProQR Therapeutics BV. For market capitalisation and broader financial context, see PRQR stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.46x | $-36.39 Million | $79.40 Million | ▼ -326.7% |
| 2023 | 0.20x | $21.55 Million | $106.59 Million | ▲ +130.9% |
| 2022 | -0.65x | $-68.51 Million | $104.64 Million | ▼ -142.5% |
| 2021 | -0.27x | $-26.01 Million | $96.35 Million | ▲ +70.4% |
| 2020 | -0.91x | $-47.06 Million | $51.61 Million | ▲ +44.8% |
| 2019 | -1.65x | $-43.97 Million | $26.61 Million | ▲ +5.5% |
| 2018 | -1.75x | $-30.68 Million | $17.55 Million | ▲ +31.1% |
| 2017 | -2.54x | $-34.95 Million | $13.78 Million | ▲ +8.0% |
| 2016 | -2.76x | $-34.22 Million | $12.41 Million | ▼ -17.4% |
| 2015 | -2.35x | $-24.23 Million | $10.31 Million | ▲ +5.0% |
| 2014 | -2.47x | $-14.46 Million | $5.84 Million | ▼ -387.3% |
| 2013 | -0.51x | $-2.33 Million | $4.59 Million | — |